FREMONT, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (PSNL), a leader in advanced genomics for precision oncology, today announced Medicare coverage of its ultrasensitive NeXT Personal® test for ...

Strategic focus shifted from cautious spending and scaling to a full embrace of growth, especially with the 170% test volume growth target for 2026 and a doubling of sales reps. Guidance language ...

Coverage marks a pivotal step in expanding access to ultra-sensitive MRD detection for breast cancer patients U.S. Medicare coverage decision reflects published, peer-reviewed clinical data ...

Some private insurers now cover the test with certain limitations, including UnitedHealthcare and Cigna, but others do not. Even in states that have adopted the test, coverage varies. Florida will add ...

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that it has received new commercial health plan coverage for the ...

TIME IS RUNNING OUT FOR CONGRESS TO APPROVE MEDICARE COVERAGE FOR A SIMPLE BLOOD TEST THAT CAN HELP DETECT CANCER IN EARLIER, MORE TREATABLE STAGES. ADVOCATES TONIGHT SAY WITHOUT MEDICARE COVERAGE, ...

WASHINGTON -- Heart transplant patient Eddie Garcia was "feeling like a million bucks" one day in the summer of 2021. He had just gotten back from a 3-mile walk, something he couldn't do prior to his ...

Only blood test approved by FDA as companion diagnostic for ORSERDU™ (elacestrant), Guardant360 CDx gains coverage by Aetna and Humana to identify eligible patients with advanced breast cancer prior ...